id	sid	tid	token	lemma	pos
dpc-1879	1	1	dermatology	dermatology	NOUN
dpc-1879	1	2	:	:	PUNCT
dpc-1879	1	3	practical	practical	ADJ
dpc-1879	1	4	and	and	CCONJ
dpc-1879	1	5	conceptual	conceptual	ADJ
dpc-1879	1	6	research	research	NOUN
dpc-1879	1	7	letter	letter	NOUN
dpc-1879	2	1	|	|	ADV
dpc-1879	2	2	dermatol	dermatol	ADJ
dpc-1879	2	3	pract	pract	NOUN
dpc-1879	2	4	concept	concept	NOUN
dpc-1879	2	5	.	.	PUNCT
dpc-1879	3	1	2022;12(2):e2022049	2022;12(2):e2022049	NUM
dpc-1879	3	2	1	1	NUM
dpc-1879	3	3	tildrakizumab	tildrakizumab	NOUN
dpc-1879	3	4	:	:	PUNCT
dpc-1879	3	5	successful	successful	ADJ
dpc-1879	3	6	response	response	NOUN
dpc-1879	3	7	in	in	ADP
dpc-1879	3	8	two	two	NUM
dpc-1879	3	9	patients	patient	NOUN
dpc-1879	3	10	with	with	ADP
dpc-1879	3	11	psoriatic	psoriatic	ADJ
dpc-1879	3	12	arthritis	arthritis	NOUN
dpc-1879	3	13	dario	dario	NOUN
dpc-1879	3	14	buononato1	buononato1	PROPN
dpc-1879	3	15	,	,	PUNCT
dpc-1879	3	16	gaetano	gaetano	PROPN
dpc-1879	3	17	licata1	licata1	PROPN
dpc-1879	3	18	,	,	PUNCT
dpc-1879	3	19	alessio	alessio	PROPN
dpc-1879	3	20	gambardella1	gambardella1	PROPN
dpc-1879	3	21	,	,	PUNCT
dpc-1879	3	22	alina	alina	PROPN
dpc-1879	3	23	de	de	X
dpc-1879	3	24	rosa1	rosa1	PROPN
dpc-1879	3	25	,	,	PUNCT
dpc-1879	3	26	giulia	giulia	PROPN
dpc-1879	3	27	calabrese1	calabrese1	PROPN
dpc-1879	3	28	,	,	PUNCT
dpc-1879	3	29	giuseppe	giuseppe	PROPN
dpc-1879	3	30	argenziano1	argenziano1	NOUN
dpc-1879	3	31	1	1	NUM
dpc-1879	3	32	dermatology	dermatology	NOUN
dpc-1879	3	33	unit	unit	NOUN
dpc-1879	3	34	,	,	PUNCT
dpc-1879	3	35	department	department	NOUN
dpc-1879	3	36	of	of	ADP
dpc-1879	3	37	mentals	mental	NOUN
dpc-1879	3	38	and	and	CCONJ
dpc-1879	3	39	physical	physical	ADJ
dpc-1879	3	40	health	health	NOUN
dpc-1879	3	41	and	and	CCONJ
dpc-1879	3	42	preventive	preventive	ADJ
dpc-1879	3	43	medicine	medicine	NOUN
dpc-1879	3	44	,	,	PUNCT
dpc-1879	3	45	university	university	PROPN
dpc-1879	3	46	of	of	ADP
dpc-1879	3	47	campania	campania	PROPN
dpc-1879	3	48	luigi	luigi	PROPN
dpc-1879	3	49	vanvitelli	vanvitelli	PROPN
dpc-1879	3	50	,	,	PUNCT
dpc-1879	3	51	naples	naples	PROPN
dpc-1879	3	52	,	,	PUNCT
dpc-1879	3	53	italy	italy	PROPN
dpc-1879	3	54	.	.	PUNCT
dpc-1879	4	1	key	key	ADJ
dpc-1879	4	2	words	word	NOUN
dpc-1879	4	3	:	:	PUNCT
dpc-1879	4	4	psoriatic	psoriatic	ADJ
dpc-1879	4	5	arthritis	arthritis	NOUN
dpc-1879	4	6	,	,	PUNCT
dpc-1879	4	7	psoriasis	psoriasis	NOUN
dpc-1879	4	8	,	,	PUNCT
dpc-1879	4	9	tildrakizumab	tildrakizumab	NOUN
dpc-1879	4	10	,	,	PUNCT
dpc-1879	4	11	treatment	treatment	NOUN
dpc-1879	4	12	citation	citation	NOUN
dpc-1879	4	13	:	:	PUNCT
dpc-1879	4	14	buononato	buononato	NOUN
dpc-1879	4	15	d	d	PROPN
dpc-1879	4	16	,	,	PUNCT
dpc-1879	4	17	licata	licata	VERB
dpc-1879	4	18	g	g	NOUN
dpc-1879	4	19	,	,	PUNCT
dpc-1879	4	20	gambardella	gambardella	VERB
dpc-1879	4	21	a	a	DET
dpc-1879	4	22	,	,	PUNCT
dpc-1879	4	23	de	de	PROPN
dpc-1879	4	24	rosa	rosa	PROPN
dpc-1879	4	25	a	a	PROPN
dpc-1879	4	26	,	,	PUNCT
dpc-1879	4	27	calabrese	calabrese	ADJ
dpc-1879	4	28	g	g	NOUN
dpc-1879	4	29	,	,	PUNCT
dpc-1879	4	30	argenziano	argenziano	ADJ
dpc-1879	4	31	g.	g.	PROPN
dpc-1879	4	32	tildrakizumab	tildrakizumab	PROPN
dpc-1879	4	33	:	:	PUNCT
dpc-1879	4	34	successfull	successfull	ADJ
dpc-1879	4	35	response	response	NOUN
dpc-1879	4	36	in	in	ADP
dpc-1879	4	37	two	two	NUM
dpc-1879	4	38	patients	patient	NOUN
dpc-1879	4	39	with	with	ADP
dpc-1879	4	40	psoriatic	psoriatic	ADJ
dpc-1879	4	41	arthritis	arthritis	NOUN
dpc-1879	4	42	.	.	PUNCT
dpc-1879	5	1	dermatol	dermatol	NOUN
dpc-1879	5	2	pract	pract	PROPN
dpc-1879	5	3	concept	concept	NOUN
dpc-1879	5	4	.	.	PUNCT
dpc-1879	6	1	2022;12(2):e2022049	2022;12(2):e2022049	X
dpc-1879	6	2	.	.	PUNCT
dpc-1879	6	3	doi	doi	PROPN
dpc-1879	6	4	:	:	PUNCT
dpc-1879	6	5	https://doi.org/10.5826/dpc.1202a49	https://doi.org/10.5826/dpc.1202a49	PROPN
dpc-1879	6	6	accepted	accept	VERB
dpc-1879	6	7	:	:	PUNCT
dpc-1879	6	8	july	july	PROPN
dpc-1879	6	9	22	22	NUM
dpc-1879	6	10	,	,	PUNCT
dpc-1879	6	11	2021	2021	NUM
dpc-1879	6	12	;	;	PUNCT
dpc-1879	6	13	published	publish	VERB
dpc-1879	6	14	:	:	PUNCT
dpc-1879	6	15	april	april	PROPN
dpc-1879	6	16	2022	2022	NUM
dpc-1879	7	1	copyright	copyright	NOUN
dpc-1879	7	2	:	:	PUNCT
dpc-1879	7	3	©	©	PROPN
dpc-1879	7	4	2022	2022	NUM
dpc-1879	7	5	buononato	buononato	NOUN
dpc-1879	7	6	et	et	NOUN
dpc-1879	7	7	al	al	PROPN
dpc-1879	7	8	.	.	PUNCT
dpc-1879	8	1	this	this	PRON
dpc-1879	8	2	is	be	AUX
dpc-1879	8	3	an	an	DET
dpc-1879	8	4	open	open	ADJ
dpc-1879	8	5	-	-	PUNCT
dpc-1879	8	6	access	access	NOUN
dpc-1879	8	7	article	article	NOUN
dpc-1879	8	8	distributed	distribute	VERB
dpc-1879	8	9	under	under	ADP
dpc-1879	8	10	the	the	DET
dpc-1879	8	11	terms	term	NOUN
dpc-1879	8	12	of	of	ADP
dpc-1879	8	13	the	the	DET
dpc-1879	8	14	creative	creative	ADJ
dpc-1879	8	15	commons	common	NOUN
dpc-1879	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-1879	8	17	license	license	NOUN
dpc-1879	8	18	(	(	PUNCT
dpc-1879	8	19	by	by	ADP
dpc-1879	8	20	-	-	PUNCT
dpc-1879	8	21	nc-4.0	nc-4.0	NOUN
dpc-1879	8	22	)	)	PUNCT
dpc-1879	8	23	,	,	PUNCT
dpc-1879	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-1879	8	25	,	,	PUNCT
dpc-1879	8	26	which	which	PRON
dpc-1879	8	27	permits	permit	VERB
dpc-1879	8	28	unrestricted	unrestricted	ADJ
dpc-1879	8	29	noncommercial	noncommercial	ADJ
dpc-1879	8	30	use	use	NOUN
dpc-1879	8	31	,	,	PUNCT
dpc-1879	8	32	distribution	distribution	NOUN
dpc-1879	8	33	,	,	PUNCT
dpc-1879	8	34	and	and	CCONJ
dpc-1879	8	35	reproduction	reproduction	NOUN
dpc-1879	8	36	in	in	ADP
dpc-1879	8	37	any	any	DET
dpc-1879	8	38	medium	medium	NOUN
dpc-1879	8	39	,	,	PUNCT
dpc-1879	8	40	provided	provide	VERB
dpc-1879	8	41	the	the	DET
dpc-1879	8	42	original	original	ADJ
dpc-1879	8	43	authors	author	NOUN
dpc-1879	8	44	and	and	CCONJ
dpc-1879	8	45	source	source	NOUN
dpc-1879	8	46	are	be	AUX
dpc-1879	8	47	credited	credit	VERB
dpc-1879	8	48	.	.	PUNCT
dpc-1879	9	1	funding	funding	NOUN
dpc-1879	9	2	:	:	PUNCT
dpc-1879	9	3	none	none	NOUN
dpc-1879	9	4	.	.	PUNCT
dpc-1879	10	1	competing	compete	VERB
dpc-1879	10	2	interests	interest	NOUN
dpc-1879	10	3	:	:	PUNCT
dpc-1879	10	4	none	none	NOUN
dpc-1879	10	5	.	.	PUNCT
dpc-1879	11	1	authorship	authorship	NOUN
dpc-1879	11	2	:	:	PUNCT
dpc-1879	11	3	all	all	DET
dpc-1879	11	4	authors	author	NOUN
dpc-1879	11	5	have	have	AUX
dpc-1879	11	6	contributed	contribute	VERB
dpc-1879	11	7	significantly	significantly	ADV
dpc-1879	11	8	to	to	ADP
dpc-1879	11	9	this	this	DET
dpc-1879	11	10	publication	publication	NOUN
dpc-1879	11	11	.	.	PUNCT
dpc-1879	12	1	corresponding	correspond	VERB
dpc-1879	12	2	author	author	NOUN
dpc-1879	12	3	:	:	PUNCT
dpc-1879	12	4	dario	dario	PROPN
dpc-1879	12	5	buononato	buononato	PROPN
dpc-1879	12	6	,	,	PUNCT
dpc-1879	12	7	md	md	PROPN
dpc-1879	12	8	,	,	PUNCT
dpc-1879	12	9	department	department	PROPN
dpc-1879	12	10	of	of	ADP
dpc-1879	12	11	dermatology	dermatology	NOUN
dpc-1879	12	12	university	university	PROPN
dpc-1879	12	13	of	of	ADP
dpc-1879	12	14	campania	campania	PROPN
dpc-1879	12	15	“	"	PUNCT
dpc-1879	12	16	luigi	luigi	PROPN
dpc-1879	12	17	vanvitelli	vanvitelli	PROPN
dpc-1879	12	18	”	"	PUNCT
dpc-1879	12	19	via	via	ADP
dpc-1879	12	20	sergio	sergio	PROPN
dpc-1879	12	21	pansini	pansini	PROPN
dpc-1879	12	22	,	,	PUNCT
dpc-1879	12	23	5	5	NUM
dpc-1879	12	24	,	,	PUNCT
dpc-1879	12	25	80131	80131	NUM
dpc-1879	12	26	napoli	napoli	PROPN
dpc-1879	12	27	,	,	PUNCT
dpc-1879	12	28	italy	italy	PROPN
dpc-1879	12	29	.	.	PUNCT
dpc-1879	13	1	e	e	X
dpc-1879	13	2	-	-	NOUN
dpc-1879	13	3	mail	mail	NOUN
dpc-1879	13	4	:	:	PUNCT
dpc-1879	13	5	dario.buononato@gmail.com	dario.buononato@gmail.com	X
dpc-1879	13	6	introduction	introduction	NOUN
dpc-1879	13	7	psoriatic	psoriatic	ADJ
dpc-1879	13	8	arthritis	arthritis	NOUN
dpc-1879	13	9	(	(	PUNCT
dpc-1879	13	10	psa	psa	NOUN
dpc-1879	13	11	)	)	PUNCT
dpc-1879	13	12	is	be	AUX
dpc-1879	13	13	a	a	DET
dpc-1879	13	14	chronic	chronic	NOUN
dpc-1879	13	15	,	,	PUNCT
dpc-1879	13	16	immune	immune	NOUN
dpc-1879	13	17	-	-	PUNCT
dpc-1879	13	18	mediated	mediate	VERB
dpc-1879	13	19	,	,	PUNCT
dpc-1879	13	20	inflammatory	inflammatory	ADJ
dpc-1879	13	21	arthropathy	arthropathy	ADJ
dpc-1879	13	22	that	that	PRON
dpc-1879	13	23	develops	develop	VERB
dpc-1879	13	24	in	in	ADP
dpc-1879	13	25	up	up	ADP
dpc-1879	13	26	to	to	PART
dpc-1879	13	27	30	30	NUM
dpc-1879	13	28	%	%	NOUN
dpc-1879	13	29	of	of	ADP
dpc-1879	13	30	patients	patient	NOUN
dpc-1879	13	31	with	with	ADP
dpc-1879	13	32	psoriasis	psoriasis	NOUN
dpc-1879	13	33	.	.	PUNCT
dpc-1879	14	1	different	different	ADJ
dpc-1879	14	2	phenotypes	phenotype	NOUN
dpc-1879	14	3	are	be	AUX
dpc-1879	14	4	recognized	recognize	VERB
dpc-1879	14	5	according	accord	VERB
dpc-1879	14	6	to	to	ADP
dpc-1879	14	7	the	the	DET
dpc-1879	14	8	joints	joint	NOUN
dpc-1879	14	9	involved	involve	VERB
dpc-1879	14	10	:	:	PUNCT
dpc-1879	14	11	distal	distal	ADJ
dpc-1879	14	12	interphalangeal	interphalangeal	ADJ
dpc-1879	14	13	predominant	predominant	ADJ
dpc-1879	14	14	,	,	PUNCT
dpc-1879	14	15	asymmetric	asymmetric	ADJ
dpc-1879	14	16	oligoarticular	oligoarticular	ADJ
dpc-1879	14	17	,	,	PUNCT
dpc-1879	14	18	symmetric	symmetric	ADJ
dpc-1879	14	19	polyarthritis	polyarthritis	NOUN
dpc-1879	14	20	,	,	PUNCT
dpc-1879	14	21	spondylitis	spondylitis	NOUN
dpc-1879	14	22	and	and	CCONJ
dpc-1879	14	23	arthritis	arthritis	NOUN
dpc-1879	14	24	mutilans	mutilan	NOUN
dpc-1879	14	25	.	.	PUNCT
dpc-1879	15	1	the	the	DET
dpc-1879	15	2	treatment	treatment	NOUN
dpc-1879	15	3	of	of	ADP
dpc-1879	15	4	psa	psa	NOUN
dpc-1879	15	5	includes	include	VERB
dpc-1879	15	6	different	different	ADJ
dpc-1879	15	7	therapeutic	therapeutic	ADJ
dpc-1879	15	8	strategies	strategy	NOUN
dpc-1879	15	9	:	:	PUNCT
dpc-1879	15	10	conventional	conventional	ADJ
dpc-1879	15	11	disease	disease	NOUN
dpc-1879	15	12	modifying	modify	VERB
dpc-1879	15	13	antirheumatic	antirheumatic	ADJ
dpc-1879	15	14	drugs	drug	NOUN
dpc-1879	15	15	(	(	PUNCT
dpc-1879	15	16	dmards	dmard	NOUN
dpc-1879	15	17	)	)	PUNCT
dpc-1879	15	18	and	and	CCONJ
dpc-1879	15	19	biologic	biologic	NOUN
dpc-1879	15	20	therapies	therapy	NOUN
dpc-1879	15	21	such	such	ADJ
dpc-1879	15	22	as	as	ADP
dpc-1879	15	23	tumor	tumor	NOUN
dpc-1879	15	24	necrosis	necrosis	NOUN
dpc-1879	15	25	factor	factor	NOUN
dpc-1879	15	26	(	(	PUNCT
dpc-1879	15	27	tnf	tnf	PROPN
dpc-1879	15	28	)	)	PUNCT
dpc-1879	15	29	inhibitors	inhibitor	NOUN
dpc-1879	15	30	,	,	PUNCT
dpc-1879	15	31	interleukins-17	interleukins-17	PROPN
dpc-1879	15	32	(	(	PUNCT
dpc-1879	15	33	il-17	il-17	NOUN
dpc-1879	15	34	)	)	PUNCT
dpc-1879	15	35	inhibitors	inhibitor	NOUN
dpc-1879	15	36	,	,	PUNCT
dpc-1879	15	37	il-12/23	il-12/23	ADJ
dpc-1879	15	38	inhibitor	inhibitor	NOUN
dpc-1879	15	39	.	.	PUNCT
dpc-1879	16	1	however	however	ADV
dpc-1879	16	2	not	not	PART
dpc-1879	16	3	all	all	DET
dpc-1879	16	4	agents	agent	NOUN
dpc-1879	16	5	used	use	VERB
dpc-1879	16	6	for	for	ADP
dpc-1879	16	7	psoriasis	psoriasis	NOUN
dpc-1879	16	8	are	be	AUX
dpc-1879	16	9	yet	yet	ADV
dpc-1879	16	10	approved	approve	VERB
dpc-1879	16	11	for	for	ADP
dpc-1879	16	12	psa	psa	NOUN
dpc-1879	16	13	including	include	VERB
dpc-1879	16	14	il-23	il-23	NOUN
dpc-1879	16	15	inhibitors	inhibitor	NOUN
dpc-1879	16	16	:	:	PUNCT
dpc-1879	16	17	there	there	PRON
dpc-1879	16	18	are	be	VERB
dpc-1879	16	19	several	several	ADJ
dpc-1879	16	20	cases	case	NOUN
dpc-1879	16	21	of	of	ADP
dpc-1879	16	22	psa	psa	NOUN
dpc-1879	16	23	successfully	successfully	ADV
dpc-1879	16	24	treated	treat	VERB
dpc-1879	16	25	with	with	ADP
dpc-1879	16	26	il-23	il-23	NOUN
dpc-1879	16	27	inhibitors	inhibitor	NOUN
dpc-1879	16	28	.	.	PUNCT
dpc-1879	17	1	case	case	NOUN
dpc-1879	17	2	presentation	presentation	NOUN
dpc-1879	17	3	we	we	PRON
dpc-1879	17	4	report	report	VERB
dpc-1879	17	5	2cases	2case	NOUN
dpc-1879	17	6	of	of	ADP
dpc-1879	17	7	patients	patient	NOUN
dpc-1879	17	8	with	with	ADP
dpc-1879	17	9	psa	psa	NOUN
dpc-1879	17	10	and	and	CCONJ
dpc-1879	17	11	psoriasis	psoriasis	NOUN
dpc-1879	17	12	(	(	PUNCT
dpc-1879	17	13	table	table	NOUN
dpc-1879	17	14	1	1	NUM
dpc-1879	17	15	)	)	PUNCT
dpc-1879	17	16	who	who	PRON
dpc-1879	17	17	successfully	successfully	ADV
dpc-1879	17	18	responded	respond	VERB
dpc-1879	17	19	to	to	ADP
dpc-1879	17	20	tildrakizumab	tildrakizumab	NOUN
dpc-1879	17	21	,	,	PUNCT
dpc-1879	17	22	an	an	DET
dpc-1879	17	23	anti	anti	ADJ
dpc-1879	17	24	-	-	ADJ
dpc-1879	17	25	il-23	il-23	ADJ
dpc-1879	17	26	antibody	antibody	NOUN
dpc-1879	17	27	approved	approve	VERB
dpc-1879	17	28	only	only	ADV
dpc-1879	17	29	for	for	ADP
dpc-1879	17	30	psoriasis	psoriasis	NOUN
dpc-1879	17	31	.	.	PUNCT
dpc-1879	18	1	in	in	ADP
dpc-1879	18	2	the	the	DET
dpc-1879	18	3	first	first	ADJ
dpc-1879	18	4	case	case	NOUN
dpc-1879	18	5	a	a	DET
dpc-1879	18	6	45	45	NUM
dpc-1879	18	7	-	-	PUNCT
dpc-1879	18	8	year	year	NOUN
dpc-1879	18	9	-	-	PUNCT
dpc-1879	18	10	old	old	ADJ
dpc-1879	18	11	man	man	NOUN
dpc-1879	18	12	came	come	VERB
dpc-1879	18	13	to	to	ADP
dpc-1879	18	14	our	our	PRON
dpc-1879	18	15	unit	unit	NOUN
dpc-1879	18	16	with	with	ADP
dpc-1879	18	17	a	a	DET
dpc-1879	18	18	10	10	NUM
dpc-1879	18	19	years	year	NOUN
dpc-1879	18	20	history	history	NOUN
dpc-1879	18	21	of	of	ADP
dpc-1879	18	22	psa	psa	NOUN
dpc-1879	18	23	and	and	CCONJ
dpc-1879	18	24	psoriasis	psoriasis	NOUN
dpc-1879	18	25	.	.	PUNCT
dpc-1879	19	1	the	the	DET
dpc-1879	19	2	patient	patient	NOUN
dpc-1879	19	3	presented	present	VERB
dpc-1879	19	4	several	several	ADJ
dpc-1879	19	5	episodes	episode	NOUN
dpc-1879	19	6	of	of	ADP
dpc-1879	19	7	dactylitis	dactylitis	NOUN
dpc-1879	19	8	with	with	ADP
dpc-1879	19	9	radiologically	radiologically	ADV
dpc-1879	19	10	documented	document	VERB
dpc-1879	19	11	damage	damage	NOUN
dpc-1879	19	12	to	to	ADP
dpc-1879	19	13	the	the	DET
dpc-1879	19	14	distal	distal	ADJ
dpc-1879	19	15	interphalangeal	interphalangeal	ADJ
dpc-1879	19	16	joints	joint	NOUN
dpc-1879	19	17	.	.	PUNCT
dpc-1879	20	1	he	he	PRON
dpc-1879	20	2	had	have	AUX
dpc-1879	20	3	been	be	AUX
dpc-1879	20	4	treated	treat	VERB
dpc-1879	20	5	with	with	ADP
dpc-1879	20	6	methotrexate	methotrexate	NOUN
dpc-1879	20	7	(	(	PUNCT
dpc-1879	20	8	20	20	NUM
dpc-1879	20	9	mg	mg	NUM
dpc-1879	20	10	/	/	SYM
dpc-1879	20	11	week	week	NOUN
dpc-1879	20	12	)	)	PUNCT
dpc-1879	20	13	for	for	ADP
dpc-1879	20	14	9	9	NUM
dpc-1879	20	15	months	month	NOUN
dpc-1879	20	16	,	,	PUNCT
dpc-1879	20	17	suspended	suspend	VERB
dpc-1879	20	18	for	for	ADP
dpc-1879	20	19	a	a	DET
dpc-1879	20	20	significant	significant	ADJ
dpc-1879	20	21	increase	increase	NOUN
dpc-1879	20	22	in	in	ADP
dpc-1879	20	23	transaminases	transaminase	NOUN
dpc-1879	20	24	(	(	PUNCT
dpc-1879	20	25	alt	alt	VERB
dpc-1879	20	26	110	110	NUM
dpc-1879	20	27	u	u	NOUN
dpc-1879	20	28	/	/	SYM
dpc-1879	20	29	l	l	NOUN
dpc-1879	20	30	,	,	PUNCT
dpc-1879	20	31	ast	ast	VERB
dpc-1879	20	32	121	121	NUM
dpc-1879	20	33	u	u	NOUN
dpc-1879	20	34	/	/	SYM
dpc-1879	20	35	l	l	NOUN
dpc-1879	20	36	)	)	PUNCT
dpc-1879	20	37	.	.	PUNCT
dpc-1879	21	1	we	we	PRON
dpc-1879	21	2	started	start	VERB
dpc-1879	21	3	treatment	treatment	NOUN
dpc-1879	21	4	with	with	ADP
dpc-1879	21	5	secukinumab	secukinumab	NOUN
dpc-1879	21	6	(	(	PUNCT
dpc-1879	21	7	300	300	NUM
dpc-1879	21	8	mg	mg	PROPN
dpc-1879	21	9	sc	sc	PROPN
dpc-1879	21	10	monthly	monthly	ADV
dpc-1879	21	11	)	)	PUNCT
dpc-1879	21	12	from	from	ADP
dpc-1879	21	13	october	october	PROPN
dpc-1879	21	14	2018	2018	NUM
dpc-1879	21	15	to	to	ADP
dpc-1879	21	16	november	november	PROPN
dpc-1879	21	17	2019	2019	NUM
dpc-1879	21	18	with	with	ADP
dpc-1879	21	19	a	a	DET
dpc-1879	21	20	partial	partial	ADJ
dpc-1879	21	21	improvement	improvement	NOUN
dpc-1879	21	22	of	of	ADP
dpc-1879	21	23	psa	psa	NOUN
dpc-1879	21	24	and	and	CCONJ
dpc-1879	21	25	skin	skin	NOUN
dpc-1879	21	26	disease	disease	NOUN
dpc-1879	21	27	,	,	PUNCT
dpc-1879	21	28	but	but	CCONJ
dpc-1879	21	29	the	the	DET
dpc-1879	21	30	patient	patient	NOUN
dpc-1879	21	31	developed	develop	VERB
dpc-1879	21	32	upper	upper	ADJ
dpc-1879	21	33	respiratory	respiratory	ADJ
dpc-1879	21	34	tract	tract	NOUN
dpc-1879	21	35	infection	infection	NOUN
dpc-1879	21	36	and	and	CCONJ
dpc-1879	21	37	the	the	DET
dpc-1879	21	38	drug	drug	NOUN
dpc-1879	21	39	was	be	AUX
dpc-1879	21	40	stopped	stop	VERB
dpc-1879	21	41	.	.	PUNCT
dpc-1879	22	1	thus	thus	ADV
dpc-1879	22	2	,	,	PUNCT
dpc-1879	22	3	the	the	DET
dpc-1879	22	4	patient	patient	NOUN
dpc-1879	22	5	received	receive	VERB
dpc-1879	22	6	tildrakizumab	tildrakizumab	NOUN
dpc-1879	22	7	at	at	ADP
dpc-1879	22	8	the	the	DET
dpc-1879	22	9	same	same	ADJ
dpc-1879	22	10	dosage	dosage	NOUN
dpc-1879	22	11	regimen	regiman	NOUN
dpc-1879	22	12	as	as	ADP
dpc-1879	22	13	in	in	ADP
dpc-1879	22	14	psoriasis	psoriasis	NOUN
dpc-1879	22	15	(	(	PUNCT
dpc-1879	22	16	100	100	NUM
dpc-1879	22	17	mg	mg	PROPN
dpc-1879	22	18	sc	sc	PROPN
dpc-1879	22	19	every	every	DET
dpc-1879	22	20	12	12	NUM
dpc-1879	22	21	weeks	week	NOUN
dpc-1879	22	22	)	)	PUNCT
dpc-1879	22	23	with	with	ADP
dpc-1879	22	24	improvement	improvement	NOUN
dpc-1879	22	25	in	in	ADP
dpc-1879	22	26	both	both	DET
dpc-1879	22	27	diseases	disease	NOUN
dpc-1879	22	28	.	.	PUNCT
dpc-1879	23	1	in	in	ADP
dpc-1879	23	2	the	the	DET
dpc-1879	23	3	second	second	ADJ
dpc-1879	23	4	case	case	NOUN
dpc-1879	23	5	a	a	DET
dpc-1879	23	6	56	56	NUM
dpc-1879	23	7	-	-	PUNCT
dpc-1879	23	8	year	year	NOUN
dpc-1879	23	9	-	-	PUNCT
dpc-1879	23	10	old	old	ADJ
dpc-1879	23	11	woman	woman	NOUN
dpc-1879	23	12	came	come	VERB
dpc-1879	23	13	to	to	ADP
dpc-1879	23	14	our	our	PRON
dpc-1879	23	15	unit	unit	NOUN
dpc-1879	23	16	with	with	ADP
dpc-1879	23	17	a	a	DET
dpc-1879	23	18	15	15	NUM
dpc-1879	23	19	years	year	NOUN
dpc-1879	23	20	history	history	NOUN
dpc-1879	23	21	of	of	ADP
dpc-1879	23	22	psa	psa	NOUN
dpc-1879	23	23	and	and	CCONJ
dpc-1879	23	24	psoriasis	psoriasis	NOUN
dpc-1879	23	25	.	.	PUNCT
dpc-1879	24	1	the	the	DET
dpc-1879	24	2	patient	patient	NOUN
dpc-1879	24	3	suffered	suffer	VERB
dpc-1879	24	4	from	from	ADP
dpc-1879	24	5	peripheral	peripheral	ADJ
dpc-1879	24	6	asymmetric	asymmetric	ADJ
dpc-1879	24	7	oligoarticular	oligoarticular	ADJ
dpc-1879	24	8	arthritis	arthritis	NOUN
dpc-1879	24	9	associated	associate	VERB
dpc-1879	24	10	with	with	ADP
dpc-1879	24	11	bilateral	bilateral	ADJ
dpc-1879	24	12	uveitis	uveitis	NOUN
dpc-1879	24	13	,	,	PUNCT
dpc-1879	24	14	treated	treat	VERB
dpc-1879	24	15	periodically	periodically	ADV
dpc-1879	24	16	with	with	ADP
dpc-1879	24	17	methotrexate	methotrexate	NOUN
dpc-1879	24	18	(	(	PUNCT
dpc-1879	24	19	15	15	NUM
dpc-1879	24	20	mg	mg	NOUN
dpc-1879	24	21	/	/	SYM
dpc-1879	24	22	week	week	NOUN
dpc-1879	24	23	)	)	PUNCT
dpc-1879	24	24	interrupted	interrupt	VERB
dpc-1879	24	25	because	because	SCONJ
dpc-1879	24	26	of	of	ADP
dpc-1879	24	27	several	several	ADJ
dpc-1879	24	28	relapses	relapse	NOUN
dpc-1879	24	29	.	.	PUNCT
dpc-1879	25	1	from	from	ADP
dpc-1879	25	2	october	october	PROPN
dpc-1879	25	3	2019	2019	NUM
dpc-1879	25	4	to	to	ADP
dpc-1879	25	5	september	september	PROPN
dpc-1879	25	6	2020	2020	NUM
dpc-1879	25	7	,	,	PUNCT
dpc-1879	25	8	she	she	PRON
dpc-1879	25	9	began	begin	VERB
dpc-1879	25	10	therapy	therapy	NOUN
dpc-1879	25	11	with	with	ADP
dpc-1879	25	12	adalimumab	adalimumab	NOUN
dpc-1879	25	13	(	(	PUNCT
dpc-1879	25	14	40	40	NUM
dpc-1879	25	15	mg	mg	PROPN
dpc-1879	25	16	sc	sc	PROPN
dpc-1879	25	17	every	every	DET
dpc-1879	25	18	2	2	NUM
dpc-1879	25	19	weeks	week	NOUN
dpc-1879	25	20	)	)	PUNCT
dpc-1879	25	21	,	,	PUNCT
dpc-1879	25	22	then	then	ADV
dpc-1879	25	23	stopped	stop	VERB
dpc-1879	25	24	for	for	ADP
dpc-1879	25	25	the	the	DET
dpc-1879	25	26	appearance	appearance	NOUN
dpc-1879	25	27	of	of	ADP
dpc-1879	25	28	itching	itching	NOUN
dpc-1879	25	29	and	and	CCONJ
dpc-1879	25	30	skin	skin	NOUN
dpc-1879	25	31	rash	rash	NOUN
dpc-1879	25	32	.	.	PUNCT
dpc-1879	26	1	given	give	VERB
dpc-1879	26	2	2	2	NUM
dpc-1879	26	3	research	research	NOUN
dpc-1879	26	4	letter	letter	NOUN
dpc-1879	26	5	|	|	ADV
dpc-1879	26	6	dermatol	dermatol	ADJ
dpc-1879	26	7	pract	pract	NOUN
dpc-1879	26	8	concept	concept	NOUN
dpc-1879	26	9	.	.	PUNCT
dpc-1879	27	1	2022;12(2):e2022049	2022;12(2):e2022049	NUM
dpc-1879	27	2	the	the	DET
dpc-1879	27	3	impossibility	impossibility	NOUN
dpc-1879	27	4	of	of	ADP
dpc-1879	27	5	carrying	carry	VERB
dpc-1879	27	6	out	out	ADP
dpc-1879	27	7	therapy	therapy	NOUN
dpc-1879	27	8	with	with	ADP
dpc-1879	27	9	il-17	il-17	NUM
dpc-1879	27	10	inhibitors	inhibitor	NOUN
dpc-1879	27	11	due	due	ADJ
dpc-1879	27	12	to	to	ADP
dpc-1879	27	13	a	a	DET
dpc-1879	27	14	suspected	suspect	VERB
dpc-1879	27	15	concomitant	concomitant	ADJ
dpc-1879	27	16	ulcerative	ulcerative	ADJ
dpc-1879	27	17	colitis	colitis	NOUN
dpc-1879	27	18	,	,	PUNCT
dpc-1879	27	19	we	we	PRON
dpc-1879	27	20	started	start	VERB
dpc-1879	27	21	therapy	therapy	NOUN
dpc-1879	27	22	with	with	ADP
dpc-1879	27	23	tildrakizumab	tildrakizumab	NOUN
dpc-1879	27	24	from	from	ADP
dpc-1879	27	25	december	december	PROPN
dpc-1879	27	26	2020	2020	NUM
dpc-1879	27	27	,	,	PUNCT
dpc-1879	27	28	getting	get	VERB
dpc-1879	27	29	a	a	DET
dpc-1879	27	30	control	control	NOUN
dpc-1879	27	31	of	of	ADP
dpc-1879	27	32	psa	psa	PROPN
dpc-1879	27	33	.	.	PUNCT
dpc-1879	28	1	conclusions	conclusion	NOUN
dpc-1879	28	2	il-23	il-23	NOUN
dpc-1879	28	3	/	/	SYM
dpc-1879	28	4	il-17	il-17	NUM
dpc-1879	28	5	cytokines	cytokine	NOUN
dpc-1879	28	6	are	be	AUX
dpc-1879	28	7	important	important	ADJ
dpc-1879	28	8	players	player	NOUN
dpc-1879	28	9	in	in	ADP
dpc-1879	28	10	the	the	DET
dpc-1879	28	11	pathogenesis	pathogenesis	NOUN
dpc-1879	28	12	of	of	ADP
dpc-1879	28	13	psa	psa	NOUN
dpc-1879	28	14	.	.	PUNCT
dpc-1879	29	1	in	in	ADP
dpc-1879	29	2	particular	particular	ADJ
dpc-1879	29	3	,	,	PUNCT
dpc-1879	29	4	il-23	il-23	NOUN
dpc-1879	29	5	stabilizes	stabilize	VERB
dpc-1879	29	6	the	the	DET
dpc-1879	29	7	th17	th17	PROPN
dpc-1879	29	8	phenotype	phenotype	NOUN
dpc-1879	29	9	,	,	PUNCT
dpc-1879	29	10	supporting	support	VERB
dpc-1879	29	11	secretion	secretion	NOUN
dpc-1879	29	12	of	of	ADP
dpc-1879	29	13	il-17	il-17	NUM
dpc-1879	29	14	which	which	PRON
dpc-1879	29	15	mediate	mediate	VERB
dpc-1879	29	16	the	the	DET
dpc-1879	29	17	epidermal	epidermal	ADJ
dpc-1879	29	18	hyperplasia	hyperplasia	NOUN
dpc-1879	29	19	and	and	CCONJ
dpc-1879	29	20	keratinocyte	keratinocyte	NOUN
dpc-1879	29	21	differentiation	differentiation	NOUN
dpc-1879	29	22	.	.	PUNCT
dpc-1879	30	1	moreover	moreover	ADV
dpc-1879	30	2	il-23	il-23	NOUN
dpc-1879	30	3	activates	activate	VERB
dpc-1879	30	4	the	the	DET
dpc-1879	30	5	production	production	NOUN
dpc-1879	30	6	of	of	ADP
dpc-1879	30	7	ltb4	ltb4	PROPN
dpc-1879	30	8	,	,	PUNCT
dpc-1879	30	9	exacerbating	exacerbate	VERB
dpc-1879	30	10	the	the	DET
dpc-1879	30	11	synovial	synovial	ADJ
dpc-1879	30	12	inflammation	inflammation	NOUN
dpc-1879	30	13	,	,	PUNCT
dpc-1879	30	14	and	and	CCONJ
dpc-1879	30	15	induces	induce	VERB
dpc-1879	30	16	osteoclast	osteoclast	ADJ
dpc-1879	30	17	differentiation	differentiation	NOUN
dpc-1879	30	18	with	with	ADP
dpc-1879	30	19	bone	bone	NOUN
dpc-1879	30	20	resorption	resorption	NOUN
dpc-1879	30	21	result	result	VERB
dpc-1879	30	22	[	[	X
dpc-1879	30	23	1	1	NUM
dpc-1879	30	24	]	]	PUNCT
dpc-1879	30	25	.	.	PUNCT
dpc-1879	31	1	we	we	PRON
dpc-1879	31	2	have	have	AUX
dpc-1879	31	3	demonstrated	demonstrate	VERB
dpc-1879	31	4	that	that	SCONJ
dpc-1879	31	5	tildrakizumab	tildrakizumab	NOUN
dpc-1879	31	6	is	be	AUX
dpc-1879	31	7	a	a	DET
dpc-1879	31	8	valid	valid	ADJ
dpc-1879	31	9	therapeutic	therapeutic	ADJ
dpc-1879	31	10	option	option	NOUN
dpc-1879	31	11	in	in	ADP
dpc-1879	31	12	patients	patient	NOUN
dpc-1879	31	13	suffering	suffer	VERB
dpc-1879	31	14	from	from	ADP
dpc-1879	31	15	psa	psa	NOUN
dpc-1879	31	16	,	,	PUNCT
dpc-1879	31	17	as	as	SCONJ
dpc-1879	31	18	it	it	PRON
dpc-1879	31	19	acts	act	VERB
dpc-1879	31	20	inhibiting	inhibit	VERB
dpc-1879	31	21	the	the	DET
dpc-1879	31	22	il-23	il-23	NOUN
dpc-1879	31	23	/	/	SYM
dpc-1879	31	24	il-17	il-17	NUM
dpc-1879	31	25	axis	axis	NOUN
dpc-1879	31	26	,	,	PUNCT
dpc-1879	31	27	the	the	DET
dpc-1879	31	28	signaling	signal	VERB
dpc-1879	31	29	pathway	pathway	NOUN
dpc-1879	31	30	primarily	primarily	ADV
dpc-1879	31	31	dysregulated	dysregulate	VERB
dpc-1879	31	32	in	in	ADP
dpc-1879	31	33	this	this	DET
dpc-1879	31	34	condition	condition	NOUN
dpc-1879	31	35	.	.	PUNCT
dpc-1879	32	1	it	it	PRON
dpc-1879	32	2	has	have	AUX
dpc-1879	32	3	never	never	ADV
dpc-1879	32	4	been	be	AUX
dpc-1879	32	5	described	describe	VERB
dpc-1879	32	6	cases	case	NOUN
dpc-1879	32	7	of	of	ADP
dpc-1879	32	8	patients	patient	NOUN
dpc-1879	32	9	with	with	ADP
dpc-1879	32	10	psa	psa	NOUN
dpc-1879	32	11	and	and	CCONJ
dpc-1879	32	12	concomitant	concomitant	ADJ
dpc-1879	32	13	psoriasis	psoriasis	NOUN
dpc-1879	32	14	with	with	ADP
dpc-1879	32	15	favorable	favorable	ADJ
dpc-1879	32	16	response	response	NOUN
dpc-1879	32	17	to	to	ADP
dpc-1879	32	18	tildrakizumab	tildrakizumab	NOUN
dpc-1879	32	19	.	.	PUNCT
dpc-1879	33	1	recent	recent	ADJ
dpc-1879	33	2	studies	study	NOUN
dpc-1879	33	3	have	have	AUX
dpc-1879	33	4	been	be	AUX
dpc-1879	33	5	published	publish	VERB
dpc-1879	33	6	on	on	ADP
dpc-1879	33	7	the	the	DET
dpc-1879	33	8	approval	approval	NOUN
dpc-1879	33	9	of	of	ADP
dpc-1879	33	10	guselkumab	guselkumab	NOUN
dpc-1879	33	11	in	in	ADP
dpc-1879	33	12	psa	psa	NOUN
dpc-1879	33	13	[	[	X
dpc-1879	33	14	2	2	NUM
dpc-1879	33	15	]	]	PUNCT
dpc-1879	33	16	:	:	PUNCT
dpc-1879	33	17	considering	consider	VERB
dpc-1879	33	18	that	that	PRON
dpc-1879	33	19	il-23	il-23	NOUN
dpc-1879	33	20	is	be	AUX
dpc-1879	33	21	the	the	DET
dpc-1879	33	22	same	same	ADJ
dpc-1879	33	23	target	target	NOUN
dpc-1879	33	24	,	,	PUNCT
dpc-1879	33	25	also	also	ADV
dpc-1879	33	26	tildrakizumab	tildrakizumab	NOUN
dpc-1879	33	27	could	could	AUX
dpc-1879	33	28	be	be	AUX
dpc-1879	33	29	a	a	DET
dpc-1879	33	30	useful	useful	ADJ
dpc-1879	33	31	therapeutic	therapeutic	ADJ
dpc-1879	33	32	option	option	NOUN
dpc-1879	33	33	for	for	ADP
dpc-1879	33	34	this	this	DET
dpc-1879	33	35	affection	affection	NOUN
dpc-1879	33	36	.	.	PUNCT
dpc-1879	34	1	further	further	ADJ
dpc-1879	34	2	studies	study	NOUN
dpc-1879	34	3	are	be	AUX
dpc-1879	34	4	required	require	VERB
dpc-1879	34	5	to	to	PART
dpc-1879	34	6	evaluate	evaluate	VERB
dpc-1879	34	7	the	the	DET
dpc-1879	34	8	efficacy	efficacy	NOUN
dpc-1879	34	9	and	and	CCONJ
dpc-1879	34	10	safety	safety	NOUN
dpc-1879	34	11	of	of	ADP
dpc-1879	34	12	tildrakizumab	tildrakizumab	NOUN
dpc-1879	34	13	in	in	ADP
dpc-1879	34	14	larger	large	ADJ
dpc-1879	34	15	cohorts	cohort	NOUN
dpc-1879	34	16	of	of	ADP
dpc-1879	34	17	patients	patient	NOUN
dpc-1879	34	18	to	to	PART
dpc-1879	34	19	consider	consider	VERB
dpc-1879	34	20	this	this	DET
dpc-1879	34	21	il-23	il-23	NOUN
dpc-1879	34	22	inhibitor	inhibitor	NOUN
dpc-1879	34	23	as	as	ADP
dpc-1879	34	24	a	a	DET
dpc-1879	34	25	new	new	ADJ
dpc-1879	34	26	promising	promising	ADJ
dpc-1879	34	27	treatment	treatment	NOUN
dpc-1879	34	28	option	option	NOUN
dpc-1879	34	29	for	for	ADP
dpc-1879	34	30	psa	psa	NOUN
dpc-1879	34	31	.	.	PUNCT
dpc-1879	35	1	references	reference	NOUN
dpc-1879	35	2	1	1	NUM
dpc-1879	35	3	.	.	PUNCT
dpc-1879	36	1	nguyen	nguyen	PROPN
dpc-1879	36	2	ct	ct	PROPN
dpc-1879	36	3	,	,	PUNCT
dpc-1879	36	4	bloch	bloch	PROPN
dpc-1879	36	5	y	y	PROPN
dpc-1879	36	6	,	,	PUNCT
dpc-1879	36	7	składanowska	składanowska	PROPN
dpc-1879	36	8	k	k	PROPN
dpc-1879	36	9	,	,	PUNCT
dpc-1879	36	10	savvides	savvide	VERB
dpc-1879	36	11	sn	sn	PROPN
dpc-1879	36	12	,	,	PUNCT
dpc-1879	36	13	adamopoulos	adamopoulos	PROPN
dpc-1879	36	14	ie	ie	X
dpc-1879	36	15	..	..	PUNCT
dpc-1879	36	16	pathophysiology	pathophysiology	NOUN
dpc-1879	36	17	and	and	CCONJ
dpc-1879	36	18	inhibition	inhibition	NOUN
dpc-1879	36	19	of	of	ADP
dpc-1879	36	20	il-23	il-23	NOUN
dpc-1879	36	21	signaling	signal	VERB
dpc-1879	36	22	in	in	ADP
dpc-1879	36	23	psoriatic	psoriatic	ADJ
dpc-1879	36	24	arthritis	arthritis	NOUN
dpc-1879	36	25	:	:	PUNCT
dpc-1879	36	26	a	a	DET
dpc-1879	36	27	molecular	molecular	ADJ
dpc-1879	36	28	insight	insight	NOUN
dpc-1879	36	29	.	.	PUNCT
dpc-1879	37	1	clin	clin	PROPN
dpc-1879	37	2	immunol	immunol	NOUN
dpc-1879	37	3	.	.	PUNCT
dpc-1879	38	1	2019;206:15	2019;206:15	NUM
dpc-1879	38	2	-	-	SYM
dpc-1879	38	3	22	22	NUM
dpc-1879	38	4	.	.	PUNCT
dpc-1879	39	1	doi	doi	NOUN
dpc-1879	39	2	:	:	PUNCT
dpc-1879	39	3	10.1016	10.1016	NUM
dpc-1879	39	4	/	/	SYM
dpc-1879	39	5	j.clim.2018.09.002	j.clim.2018.09.002	NOUN
dpc-1879	39	6	.	.	PUNCT
dpc-1879	40	1	pmid	pmid	NOUN
dpc-1879	40	2	:	:	PUNCT
dpc-1879	40	3	30196070	30196070	NUM
dpc-1879	40	4	.	.	PUNCT
dpc-1879	41	1	pmcid	pmcid	NOUN
dpc-1879	41	2	:	:	PUNCT
dpc-1879	41	3	pmc6401348	pmc6401348	ADJ
dpc-1879	41	4	.	.	PUNCT
dpc-1879	42	1	2	2	X
dpc-1879	42	2	.	.	X
dpc-1879	42	3	boehncke	boehncke	NOUN
dpc-1879	42	4	wh	wh	PROPN
dpc-1879	42	5	,	,	PUNCT
dpc-1879	42	6	brembilla	brembilla	PROPN
dpc-1879	42	7	nc	nc	PROPN
dpc-1879	42	8	,	,	PUNCT
dpc-1879	42	9	nissen	nissen	PROPN
dpc-1879	42	10	mj	mj	PROPN
dpc-1879	42	11	.	.	PROPN
dpc-1879	42	12	guselkumab	guselkumab	PROPN
dpc-1879	42	13	:	:	PUNCT
dpc-1879	42	14	the	the	DET
dpc-1879	42	15	first	first	ADJ
dpc-1879	42	16	selective	selective	ADJ
dpc-1879	42	17	il-23	il-23	ADJ
dpc-1879	42	18	inhibitor	inhibitor	NOUN
dpc-1879	42	19	for	for	ADP
dpc-1879	42	20	active	active	ADJ
dpc-1879	42	21	psoriatic	psoriatic	ADJ
dpc-1879	42	22	arthritis	arthritis	NOUN
dpc-1879	42	23	in	in	ADP
dpc-1879	42	24	adults	adult	NOUN
dpc-1879	42	25	.	.	PUNCT
dpc-1879	43	1	expert	expert	NOUN
dpc-1879	43	2	rev	rev	VERB
dpc-1879	43	3	clin	clin	PROPN
dpc-1879	43	4	immunol	immunol	PROPN
dpc-1879	43	5	.	.	PUNCT
dpc-1879	44	1	2021;17(1):5	2021;17(1):5	NUM
dpc-1879	44	2	-	-	SYM
dpc-1879	44	3	13	13	NUM
dpc-1879	44	4	.	.	PUNCT
dpc-1879	45	1	doi	doi	PROPN
dpc-1879	45	2	10.1080/1744666x.2020.1857733	10.1080/1744666x.2020.1857733	PROPN
dpc-1879	45	3	.	.	PUNCT
dpc-1879	46	1	pmid	pmid	NOUN
dpc-1879	46	2	:	:	PUNCT
dpc-1879	46	3	33251833	33251833	NUM
dpc-1879	46	4	.	.	PUNCT
dpc-1879	47	1	table	table	NOUN
dpc-1879	47	2	1	1	NUM
dpc-1879	47	3	.	.	PUNCT
dpc-1879	48	1	patients	patient	NOUN
dpc-1879	48	2	clinical	clinical	ADJ
dpc-1879	48	3	details	detail	NOUN
dpc-1879	48	4	with	with	ADP
dpc-1879	48	5	tildrakizumab	tildrakizumab	NOUN
dpc-1879	48	6	treatment	treatment	NOUN
dpc-1879	48	7	for	for	ADP
dpc-1879	48	8	psoriatic	psoriatic	ADJ
dpc-1879	48	9	arthritis	arthritis	NOUN
dpc-1879	48	10	patient	patient	NOUN
dpc-1879	48	11	1	1	NUM
dpc-1879	48	12	patient	patient	NOUN
dpc-1879	48	13	2	2	NUM
dpc-1879	48	14	gender	gender	NOUN
dpc-1879	48	15	male	male	ADJ
dpc-1879	48	16	female	female	ADJ
dpc-1879	48	17	age	age	NOUN
dpc-1879	48	18	,	,	PUNCT
dpc-1879	48	19	years	year	NOUN
dpc-1879	48	20	45	45	NUM
dpc-1879	48	21	56	56	NUM
dpc-1879	48	22	psoriatic	psoriatic	ADJ
dpc-1879	48	23	arthritis	arthritis	NOUN
dpc-1879	48	24	phenotype	phenotype	NOUN
dpc-1879	48	25	distal	distal	ADJ
dpc-1879	48	26	interphalangeal	interphalangeal	ADJ
dpc-1879	48	27	joints	joint	NOUN
dpc-1879	48	28	asymmetric	asymmetric	ADJ
dpc-1879	48	29	oligoarticular	oligoarticular	ADJ
dpc-1879	48	30	joints	joint	NOUN
dpc-1879	48	31	systemic	systemic	ADJ
dpc-1879	48	32	involvement	involvement	NOUN
dpc-1879	48	33	psoriasis	psoriasis	NOUN
dpc-1879	48	34	psoriasis	psoriasis	NOUN
dpc-1879	48	35	uveitis	uveitis	NOUN
dpc-1879	48	36	treatment	treatment	NOUN
dpc-1879	48	37	before	before	ADP
dpc-1879	48	38	tildrakizumab	tildrakizumab	NOUN
dpc-1879	48	39	methotrexate	methotrexate	PROPN
dpc-1879	48	40	secukinumab	secukinumab	PROPN
dpc-1879	48	41	methotrexate	methotrexate	PROPN
dpc-1879	48	42	adalimumab	adalimumab	NOUN